Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
The week started with positive tidings from Pfizer Inc. (NYSE: PFE) and its German partner BioNTech SE – ADR (NASDAQ: BNTX), which reported positive interim Phase 3 data for their jointly developed mRNA vaccine against the COVID-19 coronavirus.
Supernus Pharmaceuticals Inc (NASDAQ: SUPN), meanwhile, came under pressure after the FDA rejected its ADHD drug.
Earnings news flow continued, but the week was silent on the IPO front. Multiple conferences got underway during the week, giving biopharma companies a chance to show new data on products they're investigating.
Here are the key catalysts for the week from Nov. 13.
American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov. 13-15
American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting, Digital Experience: Nov. 13-16
Guggenheim Healthcare Talks, Idea Forum, 2nd Annual Neuro/Immunology Day: Nov. 16
Stifel 2020 Virtual Healthcare Conference: Nov. 16-18
Jefferies Virtual London Healthcare Conference: Nov. 17-19
Wolfe Research Virtual Healthcare Conference: Nov. 18-19
Connective Tissue Oncology Society, or CTOS, Virtual Annual Meeting: Nov. 18-21
SVB Leerink Oncology Day: Nov. 19
2020 Society for Neuro-Oncology, or SNO, Virtual Meeting: Nov. 19-21
The FDA is set to rule on Alkermes Plc's (NASDAQ: ALKS) NDA for ALKS 3831 in schizophrenia and bipolar I disorder. (Sunday)
Also on Sunday, the fate of Adamis Pharmaceuticals Corp's (NASDAQ: ADMP) Zimhi, an investigational treatment for opioid overdose, is to be decided by the FDA.
The FDA has set a PDUFA date of Nov. 16 for Bristol-Myers Squibb Co's (NYSE: BMY) BLA for liso-cel as a treatment option for patients with relapsed or refractory large B-cell lymphoma after at least two prior therapies. (Monday)
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) awaits a decisive moment with the FDA on Nov. 20 with respect to its NDA for Lonfarnib in progeria and progeroid laminopathies. (Friday)
Clinical Readout/Data Presentations AAO Meeting Presentations
Lineage Cell Therapeutics Inc (NYSE: LCTX): updated interim results from the ongoing Phase 1/2a study of its lead product candidate OpRegen in dry age-related macular degeneration. (Sunday); the company has also scheduled a call with key opinion leaders Tuesday, 4 pm ET, to discuss the data.
Albireo Pharma Inc (NASDAQ: ALBO): new data from a Phase 3 study of odevixibat in progressive familial intrahepatic cholestasis (Sunday)
Inventiva ADR Representing Ord Shs (NASDAQ: IVA): new data from the NATIVE Phase 2b clinical trial evaluating lanifibranor for NASH, focusing on the efficacy of lanifibranor in type-2 diabetic patients and its positive effect on key plasma biomarkers (Sunday)
Akero Therapeutics Inc (NASDAQ: AKRO): additional data analysis from the Phase 2a BALANCED study of efruxifermin in non-alcoholic steatohepatitis (Sunday)
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): Updated Phase 1 data for RG6346 in HBV infection (Monday)
CymaBay Therapeutics Inc (NASDAQ: CBAY): a late-breaking presentation highlighting results from the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (Monday)
SNO Meeting Presentations
VBI Vaccines Inc (NASDAQ: VBIV): data from Part B of the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (Thursday)
Kintara Therapeutics Inc (NASDAQ: KTRA): update on Phase 2 studies of VAL-083 in MGMT-unmethylated Recurrent Glioblastoma Multiforme (Thursday)
Plus Therapeutics Inc (NASDAQ: PSTV): new interim data from the ongoing NIH-sponsored ReSPECT Phase 1 clinical trial evaluating its lead investigational asset, Rhenium NanoLiposome in patients with recurrent glioblastoma (Thursday)
Karyopharm Therapeutics Inc (NASDAQ: KPTI): data from the Phase 3 portion of the SEAL study of Xpovio in advanced dedifferentiated liposarcoma
Cogent Biosciences Inc (NASDAQ: COGT): final clinical data from its Phase 1/2 study of PLX9486 in gastrointestinal stromal tumors
Standalone Data Readouts
Avrobio Inc (NASDAQ: AVRO) will announce at its Virtual R&D Day scheduled for Tuesday additional details on its new Hunter syndrome program, while also sharing new data on its three clinical programs, including initial clinical data from its Gaucher disease program.
Pfizer and BioNTech expect safety data milestone to be achieved in the third week of November and plan for emergency use authorization shortly after.
Moderna could release interim Phase 3 readout for its coronavirus vaccine candidate, given it has said it has reached the mandated number of cases for analysis.
Edap Tms SA (NASDAQ: EDAP) (after the close)
Precipio Inc (NASDAQ: PRPO) (after the close)
Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open)
San Diego, California-based Maravai Lifsciences Holding, Inc. is planning to sell in an initial public offering 50 million shares of its common stock at a price range of $24-$27. The company, which provides critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases, said its shares will be listed on the Nasdaq under the ticker symbol MRVI.
Sotera Health Company,, a sterilization, lab testing and advisory services company, has filed a prospectus with the SEC to offer 46.6 million shares of its common stock, which are to be priced between $20 and $23. The Broadview Heights, Ohio-based company has applied for listing its shares on the Nasdaq under the ticker symbol SHC.
IPO Quiet Period Expiry
Foghorn Therapeutics Inc. (NASDAQ: FHTX)
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.